Zymeworks Inc. (ZYME)
Zymeworks Approaching A Moment Of Truth With Zanidatamab
ZYME's zanidatamab is under regulatory review for the treatment of second-line HER2-positive biliary tract cancer, with potential US approval in November 2024. Subsequent approval in the same indication could follow in the EU as early as Q2 '25, and in China in H2 '25. A readout from the HERIZON-GEA-01 study of zanidatamab in gastroesophageal adenocarcinoma in Q2 '25 represents a major clinical catalyst for ZYME.
Zymeworks Inc. (ZYME) Q2 2024 Earnings Call Transcript
Zymeworks Inc. (NASDAQ:ZYME ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Shrinal Inamdar - Director, Investor Relations Bijal Desai - Vice President-Finance & Strategy Paul Moore - Chief Scientific Officer Ken Galbraith - Chair & Chief Executive Officer Pranshul Chauhan - Associate Medical Director Conference Call Participants Stephen Willey - Stifel Jon Miller - Evercore Robert Burns - H.C. Wainwright Operator Thank you for standing by.
Zymeworks Inc. (ZYME) Reports Q2 Loss, Misses Revenue Estimates
Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.76 per share a year ago.
Zymeworks Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- ZYME
NEW YORK, NY / ACCESSWIRE / May 31, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zymeworks Inc. ("Zymeworks") (NASDAQ:ZYME) concerning possible violations of federal securities laws. Zymeworks disclosed, on April 1, 2024, that it had removed Christopher Astle ("Astle") from the positions of Senior Vice President ("SVP") and Chief Financial Officer ("CFO"), effective immediately.
Levi & Korsinsky Reminds Zymeworks Investors of the Ongoing Investigation into Potential Violations of Securities Laws - ZYME
NEW YORK, NY / ACCESSWIRE / May 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zymeworks Inc. ("Zymeworks") (NASDAQ:ZYME) concerning possible violations of federal securities laws. Zymeworks disclosed, on April 1, 2024, that it had removed Christopher Astle ("Astle") from the positions of Senior Vice President ("SVP") and Chief Financial Officer ("CFO"), effective immediately.
Lost Money on Zymeworks Inc.(ZYME)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / May 17, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zymeworks Inc. ("Zymeworks") (NASDAQ:ZYME) concerning possible violations of federal securities laws. Zymeworks disclosed, on April 1, 2024, that it had removed Christopher Astle ("Astle") from the positions of Senior Vice President ("SVP") and Chief Financial Officer ("CFO"), effective immediately.
